Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBT Margin: 2020-2025

Historic EBT Margin for GeneDx Holdings (WGS) over the last 6 years, with Sep 2025 value amounting to -6.33%.

  • GeneDx Holdings' EBT Margin rose 455.00% to -6.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.62%, marking a year-over-year increase of 3214.00%. This contributed to the annual value of -17.23% for FY2024, which is 7000.00% up from last year.
  • GeneDx Holdings' EBT Margin amounted to -6.33% in Q3 2025, which was down 161.52% from 10.29% recorded in Q2 2025.
  • GeneDx Holdings' 5-year EBT Margin high stood at 75.80% for Q3 2021, and its period low was -503.13% during Q4 2022.
  • In the last 3 years, GeneDx Holdings' EBT Margin had a median value of -32.55% in 2024 and averaged -40.52%.
  • In the last 5 years, GeneDx Holdings' EBT Margin tumbled by 43,361bps in 2022 and then skyrocketed by 45,753bps in 2023.
  • Over the past 5 years, GeneDx Holdings' EBT Margin (Quarterly) stood at -69.52% in 2021, then crashed by 43,361bps to -503.13% in 2022, then surged by 45,753bps to -45.60% in 2023, then spiked by 5,126bps to 5.66% in 2024, then soared by 455bps to -6.33% in 2025.
  • Its EBT Margin was -6.33% in Q3 2025, compared to 10.29% in Q2 2025 and -6.98% in Q1 2025.